OBJECTIVES: To describe the incidence and risk factors for verrucae in HIV-infected and uninfected women. DESIGN AND METHODS: A prospective study of 1790 HIV-infected and 772 uninfected women. Skin examinations and interviews were performed every 6 months over an 8-year study period. Data collected at each visit included antiretroviral therapy use since the prior visit, CD4 counts, HIV RNA loads, and location, description, and diagnosis of verrucae. Incidence rates of cutaneous and anogenital warts were determined. RESULTS: Unadjusted cumulative incidence of cutaneous warts for HIV-uninfected women was 6.6%, 6.7% for HIV-infected women who initiated HAART, and 8.4% for HIV-infected, HAART-naïve women. The unadjusted cumulative incidence of anogenital verrucae for HIV-uninfected women was 9.3%, 28.4% for HIV-infected women who initiated HAART, and 25.1% for HIV-infected women who were HAART-naïve. Multivariate proportional hazard models revealed the following significant factors for the development of cutaneous verrucae among HIV-infected women: Black race [relative hazard (RH) = 0.50] and Hispanic ethnicity (RH = 0.38), compared to White race. Risk factors for anogenital verrucae were: more recent recruitment (RH = 0.63), human papillomavirus infection at baseline (RH = 1.85), decade of age (RH = 0.82), current smoker (RH = 1.40), lowest CD4 count (per 100 cells/microl) in the past 4 years (RH = 0.85), and log10 higher HIV viral load at the prior visit (RH = 1.34). CONCLUSION: HIV-infected women had a significantly increased cumulative incidence of anogenital verrucae compared to HIV-uninfected women. Although HAART did not alter the risk of developing skin or anogenital warts, those with higher CD4 cell counts and lower HIV RNA levels had a lower risk of developing anogenital warts.
OBJECTIVES: To describe the incidence and risk factors for verrucae in HIV-infected and uninfected women. DESIGN AND METHODS: A prospective study of 1790 HIV-infected and 772 uninfected women. Skin examinations and interviews were performed every 6 months over an 8-year study period. Data collected at each visit included antiretroviral therapy use since the prior visit, CD4 counts, HIV RNA loads, and location, description, and diagnosis of verrucae. Incidence rates of cutaneous and anogenital warts were determined. RESULTS: Unadjusted cumulative incidence of cutaneous warts for HIV-uninfectedwomen was 6.6%, 6.7% for HIV-infectedwomen who initiated HAART, and 8.4% for HIV-infected, HAART-naïve women. The unadjusted cumulative incidence of anogenital verrucae for HIV-uninfectedwomen was 9.3%, 28.4% for HIV-infectedwomen who initiated HAART, and 25.1% for HIV-infectedwomen who were HAART-naïve. Multivariate proportional hazard models revealed the following significant factors for the development of cutaneous verrucae among HIV-infectedwomen: Black race [relative hazard (RH) = 0.50] and Hispanic ethnicity (RH = 0.38), compared to White race. Risk factors for anogenital verrucae were: more recent recruitment (RH = 0.63), human papillomavirus infection at baseline (RH = 1.85), decade of age (RH = 0.82), current smoker (RH = 1.40), lowest CD4 count (per 100 cells/microl) in the past 4 years (RH = 0.85), and log10 higher HIV viral load at the prior visit (RH = 1.34). CONCLUSION:HIV-infectedwomen had a significantly increased cumulative incidence of anogenital verrucae compared to HIV-uninfectedwomen. Although HAART did not alter the risk of developing skin or anogenital warts, those with higher CD4 cell counts and lower HIV RNA levels had a lower risk of developing anogenital warts.
Authors: F B Lillo; D Ferrari; F Veglia; M Origoni; M A Grasso; S Lodini; E Mastrorilli; G Taccagni; A Lazzarin; C Uberti-Foppa Journal: J Infect Dis Date: 2001-08-09 Impact factor: 5.226
Authors: Michael J Silverberg; Linda Ahdieh; Alvaro Munoz; Kathryn Anastos; Robert D Burk; Susan Cu-Uvin; Ann Duerr; Ruth M Greenblatt; Robert S Klein; Stewart Massad; Howard Minkoff; Laila Muderspach; Joel Palefsky; Eva Piessens; Paula Schuman; Heather Watts; Keerti V Shah Journal: Sex Transm Dis Date: 2002-08 Impact factor: 2.830
Authors: Amanda Mocroft; Ole Kirk; Nathan Clumeck; Panaglotis Gargalianos-Kakolyris; Hanna Trocha; Nelly Chentsova; Francisco Antunes; Hans-Jürgen Stellbrink; Andrew N Phillips; Jens D Lundgren Journal: Cancer Date: 2004-06-15 Impact factor: 6.860
Authors: Linda Ahdieh-Grant; Rui Li; Alexandra M Levine; L Stewart Massad; Howard D Strickler; Howard Minkoff; Michael Moxley; Joel Palefsky; Henry Sacks; Robert D Burk; Stephen J Gange Journal: J Natl Cancer Inst Date: 2004-07-21 Impact factor: 13.506
Authors: L Stewart Massad; Michael J Silverberg; Gayle Springer; Howard Minkoff; Nancy Hessol; Joel M Palefsky; Howard D Strickler; Alexandra M Levine; Henry S Sacks; Michael Moxley; D Heather Watts Journal: Am J Obstet Gynecol Date: 2004-05 Impact factor: 8.661
Authors: L Stewart Massad; Xianhong Xie; Teresa Darragh; Howard Minkoff; Alexandra M Levine; D Heather Watts; Rodney L Wright; Gypsyamber D'Souza; Christine Colie; Howard D Strickler Journal: Obstet Gynecol Date: 2011-10 Impact factor: 7.661
Authors: George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim Journal: Pediatr Infect Dis J Date: 2013-11 Impact factor: 2.129
Authors: Myron J Levin; Anna-Barbara Moscicki; Lin-Ye Song; Terrence Fenton; William A Meyer; Jennifer S Read; Edward L Handelsman; Barbara Nowak; Carlos A Sattler; Alfred Saah; David R Radley; Mark T Esser; Adriana Weinberg Journal: J Acquir Immune Defic Syndr Date: 2010-10 Impact factor: 3.731
Authors: Hung N Luu; E Susan Amirian; Wenyaw Chan; R Palmer Beasley; Linda B Piller; Michael E Scheurer Journal: J Infect Dis Date: 2012-01-13 Impact factor: 5.226
Authors: Andrea J Low; Tim Clayton; Issouf Konate; Nicolas Nagot; Abdoulaye Ouedraogo; Charlotte Huet; Marie-Noelle Didelot-Rousseau; Michel Segondy; Philippe Van de Perre; Philippe Mayaud Journal: BMC Infect Dis Date: 2011-01-20 Impact factor: 3.090
Authors: Admire Chikandiwa; Pedro T Pisa; Etienne E Muller; Catherine Tamalet; Philippe Mayaud; Matthew F Chersich; Sinead Delany-Moretlwe Journal: Sex Transm Dis Date: 2019-05 Impact factor: 2.830
Authors: Admire Chikandiwa; Helen Kelly; Bernard Sawadogo; Jean Ngou; Pedro T Pisa; Lorna Gibson; Marie-Noelle Didelot; Nicolas Meda; Helen A Weiss; Michel Segondy; Philippe Mayaud; Sinead Delany-Moretlwe Journal: PLoS One Date: 2018-05-01 Impact factor: 3.240